AI Health App MVPs: Evidence to Require Before a Pilot
Before piloting an AI feature in a health app, define its intended use, test it against representative cases, and prove that users can reach safe human review.
Reports about AI technology and skin cancer appointments have brought attention to where AI may fit in health services. They do not, by themselves, demonstrate that a proposed mobile feature is accurate, safe, or suitable for a particular user. For a product team, the practical question is narrower: what evidence must exist before a pilot exposes people to an AI-enabled health workflow? Start by defining what the feature does and does not do, then connect that intended use to evaluation, escalation, and monitoring. This article offers a pre-pilot framework for teams deciding whether an AI health app MVP is ready for a limited, controlled test.
Define the feature’s intended use and boundaries
Write a one-sentence intended-use statement before choosing a model or building a polished interface. Specify the user, the information the feature receives, the output it provides, and the decision it is meant to support. State explicitly whether it offers general information, helps organise a conversation with a professional, or makes a clinical recommendation. Those are not interchangeable product claims. The intended use should determine who can access the feature, what inputs it accepts, which situations are out of scope, and what the app tells a user when it cannot respond reliably.
For a hypothetical skin concern app, a low-risk MVP might help a user record a concern and prepare questions for a clinician, while clearly directing urgent or worrying symptoms to appropriate care. That is different from claiming to diagnose cancer or rule it out. Map each screen, notification, and marketing statement against the intended-use boundary; a disclaimer cannot correct a workflow that effectively makes a diagnosis. Before the pilot, ask the relevant clinical, privacy, legal, and regulatory specialists to review the proposed use in the jurisdictions where it will operate.
- Document intended user, purpose, excluded uses, required inputs, and the action users may reasonably take from an output.
- Check that product language and actual app behaviour communicate the same limits.
Require evaluation evidence tied to the real workflow
A model score alone is not a pilot-readiness decision. Require an evaluation plan that describes the reference standard, the cases included, how cases were selected, and who judged the outputs. Test the feature on data relevant to the intended users and operating context; record important subgroups and known gaps rather than assuming a result transfers across populations or devices. Examine false reassurance and unnecessary escalation as separate failure modes. The acceptable balance depends on the feature’s role and the harm a mistaken output could cause, so set thresholds with qualified clinical and product input before reviewing results.
Evaluate the whole mobile interaction as well as the model: image capture or form entry, poor input quality, network interruption, confusing wording, and the user’s likely next step. For the hypothetical skin concern workflow, test examples where the feature should not offer a confident result, including inadequate inputs and cases outside its defined scope. Review whether the app communicates uncertainty and makes the escalation route easy to find. Keep versioned records of the dataset, model, prompts or configuration, evaluation protocol, results, and known limitations so the pilot team can identify exactly what was assessed.
- Require written pass criteria and a documented failure review before enrolling pilot users.
- Keep a traceable record of model and app versions used in each evaluation.
Make escalation and monitoring part of the MVP
A pilot needs an operational path for cases the AI cannot safely handle. Decide who reviews an escalation, what information they receive, how quickly the workflow is expected to respond, and what the app tells the user while they wait. Do not imply that a human is watching if the service has no staffed review process. Include a safe fallback when the model, an integration, or the network is unavailable. Confirm that support teams know how to handle reports of harmful, misleading, or unexpected outputs, and establish who can pause the feature.
Set monitoring measures before launch: usage and completion, input quality, escalation frequency, user-reported problems, and output patterns that may indicate a change in performance. Where feasible and appropriate, review outcomes against a qualified reference, while respecting consent and data-protection requirements. Define alert thresholds, an owner for each alert, a review cadence, and the authority to disable or roll back the feature. A pilot is not permission to learn at users’ expense; limit participants and exposure, obtain required approvals, and make the stop conditions explicit in the pilot plan.
- Run a tabletop exercise for an unsafe output, failed escalation, and unavailable AI service.
- Name a monitoring owner and document pause, rollback, and incident-reporting steps.
A health AI pilot is ready when the team can show a clear intended use, evidence that addresses the real workflow and its failure modes, and an operational plan for escalation and monitoring. These requirements shape MVP scope: they may mean fewer features, a narrower user group, or a human-reviewed workflow before broader exposure. Treat the pilot as a controlled evaluation with defined pass and stop criteria, not as proof of clinical effectiveness. The reports behind the current trend signal provide context for the question; only evidence for the proposed app and use can answer it.